NCT07540884

Brief Summary

The purpose of this post-market clinical follow-up (PMCF) study is to describe the effectiveness and safety of Tears Naturale® Free and Tears Naturale® II lubricant eye drops in subjects experiencing dry eye (DE) symptoms.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
3mo left

Started Apr 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

5 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress30%
Apr 2026Aug 2026

Study Start

First participant enrolled

April 1, 2026

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

April 15, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 21, 2026

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2026

Last Updated

April 21, 2026

Status Verified

April 1, 2026

Enrollment Period

4 months

First QC Date

April 15, 2026

Last Update Submit

April 15, 2026

Conditions

Keywords

lubricating eye dropsdry eyesartificial tears

Outcome Measures

Primary Outcomes (1)

  • Mean Impact of Dry Eye on Everyday Life - Symptom Bother Module (IDEEL - SB) Score

    The IDEEL SB module is a 20-question, patient-reported outcome questionnaire that assesses the subject's symptoms of dry eye. For each question, the subject selected a single response for both eyes, where 0="None of the time" (Q1) or "I did not have this symptom/Not Applicable" (Q2-20) to 4="All of the time" (Q1) or "Very Much" (Q2-20). The overall Symptom Bother score is calculated as the mean value of the non-missing item scores (Q1-20) multiplied by 25, for an overall resultant score ranging from 0 to 100. Higher scores indicate greater symptom bother.

    Screening/Baseline Visit (Day 1), Day 30

Study Arms (2)

Tears Naturale Free

EXPERIMENTAL

One to two drops of artificial tears per eye as needed for 30 days (-2/+5 days)

Other: Tears Naturale Free lubricating eye drops

Tears Naturale II

EXPERIMENTAL

One to two drops of artificial tears per eye as needed for 30 days (-2/+5 days)

Other: Tears Naturale II lubricating eye drops

Interventions

Commercially available, preservative free, artificial tear product containing dextran 70 and hypromellose. Artificial tear products are designed to relieve dryness and irritation by supplementing and stabilizing the tear film.

Tears Naturale Free

Commercially available, artificial tear product containing dextran 70 and hypromellose with a gentle preservative for multi-dose use. Artificial tear products are designed to relieve dryness and irritation by supplementing and stabilizing the tear film.

Tears Naturale II

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Able to read, understand, and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form in English or French.
  • Able to attend all study visits as required as per protocol.
  • Mild to moderate dry eye disease.
  • Willing to discontinue use of all habitual artificial tear supplements and use only the study device for the entire study duration.

You may not qualify if:

  • Any known allergic reactions to the study products or its ingredients.
  • Ocular injury to either eye in the past 3 months prior to screening.
  • Ocular surgery within the previous 6 months or ocular surgery planned during the study.
  • Use of any systemic medication known to cause dry eye for less than 1 month before the Screening/Baseline visit.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Integra Eyecare Centre

Burnaby, British Columbia, V5E 1G3, Canada

Location

The Medical Arts Health Research Group

Kelowna, British Columbia, V1Y 4N7, Canada

Location

Eyes on Sheppard

North York, Ontario, M2N 3A1, Canada

Location

Dr. Shalu Pal & Associates

Toronto, Ontario, M5R 2A5, Canada

Location

Institut de L'Oeil des Laurentides

Boisbriand, Quebec, J7H 0E8, Canada

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Study Officials

  • Clinical Trial Lead, Dry Eye

    Alcon Research, LLC

    STUDY DIRECTOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 15, 2026

First Posted

April 21, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

August 1, 2026

Last Updated

April 21, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations